| Mohammad Luay Alkotob, MD, FACC, FSCAI | |
|
6122 W Pierson Rd, Unit 1, Flushing, MI 48433-3104 | |
| (810) 600-3399 | |
| (810) 600-3398 |
| Full Name | Mohammad Luay Alkotob |
|---|---|
| Gender | Male |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 28 Years |
| Location | 6122 W Pierson Rd, Flushing, Michigan |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1598792830 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 35088032 (Ohio) | Secondary |
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 4301089854 (Michigan) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Hurley Medical Center | Flint, MI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Hurley Medical Center | 2961308481 | 264 |
| Advanced Cardiovascular Clinic Pc | 7911056882 | 7 |
News Archive
The Hospital Universitario Donostia (at the city of Donostia-San Sebasti-n in the Basque province of Gipuzkoa) has incorporated a new glioblastoma multiforme treatment protocol, which could be the starting point for a more effective treatment of this type of cancer. Doctor Nicol-s Sampr-n, specialist in Neurosurgery at the hospital, has presented his PhD at the University of the Basque Country (UPV/EHU) based on the first results of the new treatment method. The work is entitled Glioblastoma multiforme. Analysis of survival and prognostic factors.
Stephen Maturo, MD, of Boston, MA, will receive the first place Charles Ferguson Clinical Science Award for outstanding achievement in the field of pediatric otolaryngology for his research paper titled "Intraoperative Laryngeal Electromyography in Children with Vocal Fold Mobility: Results of a Multicenter Longitudinal Study," during their annual meeting, April 29 - May 1, 2011, in Chicago, IL.
Neuroscientists from the University of Chicago argue that research on how memories form in the brain should consider activity of groups of brain cells working together, not just the connections between them.
Omthera Pharmaceuticals, Inc., a privately-held emerging specialty pharmaceuticals company, today announced that it has reached an agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the design of its planned Phase III registration clinical trial of Epanova™, the Company's lead compound for the treatment of patients with very high triglycerides. Epanova is an Omega 3 fatty acid containing a novel formulation of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).
› Verified 2 days ago
| Entity Name | Hurley Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1982630844 PECOS PAC ID: 2961308481 Enrollment ID: O20031208000375 |
News Archive
The Hospital Universitario Donostia (at the city of Donostia-San Sebasti-n in the Basque province of Gipuzkoa) has incorporated a new glioblastoma multiforme treatment protocol, which could be the starting point for a more effective treatment of this type of cancer. Doctor Nicol-s Sampr-n, specialist in Neurosurgery at the hospital, has presented his PhD at the University of the Basque Country (UPV/EHU) based on the first results of the new treatment method. The work is entitled Glioblastoma multiforme. Analysis of survival and prognostic factors.
Stephen Maturo, MD, of Boston, MA, will receive the first place Charles Ferguson Clinical Science Award for outstanding achievement in the field of pediatric otolaryngology for his research paper titled "Intraoperative Laryngeal Electromyography in Children with Vocal Fold Mobility: Results of a Multicenter Longitudinal Study," during their annual meeting, April 29 - May 1, 2011, in Chicago, IL.
Neuroscientists from the University of Chicago argue that research on how memories form in the brain should consider activity of groups of brain cells working together, not just the connections between them.
Omthera Pharmaceuticals, Inc., a privately-held emerging specialty pharmaceuticals company, today announced that it has reached an agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the design of its planned Phase III registration clinical trial of Epanova™, the Company's lead compound for the treatment of patients with very high triglycerides. Epanova is an Omega 3 fatty acid containing a novel formulation of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).
› Verified 2 days ago
| Entity Name | Advanced Cardiovascular Clinic Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1104067487 PECOS PAC ID: 7911056882 Enrollment ID: O20090526000039 |
News Archive
The Hospital Universitario Donostia (at the city of Donostia-San Sebasti-n in the Basque province of Gipuzkoa) has incorporated a new glioblastoma multiforme treatment protocol, which could be the starting point for a more effective treatment of this type of cancer. Doctor Nicol-s Sampr-n, specialist in Neurosurgery at the hospital, has presented his PhD at the University of the Basque Country (UPV/EHU) based on the first results of the new treatment method. The work is entitled Glioblastoma multiforme. Analysis of survival and prognostic factors.
Stephen Maturo, MD, of Boston, MA, will receive the first place Charles Ferguson Clinical Science Award for outstanding achievement in the field of pediatric otolaryngology for his research paper titled "Intraoperative Laryngeal Electromyography in Children with Vocal Fold Mobility: Results of a Multicenter Longitudinal Study," during their annual meeting, April 29 - May 1, 2011, in Chicago, IL.
Neuroscientists from the University of Chicago argue that research on how memories form in the brain should consider activity of groups of brain cells working together, not just the connections between them.
Omthera Pharmaceuticals, Inc., a privately-held emerging specialty pharmaceuticals company, today announced that it has reached an agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the design of its planned Phase III registration clinical trial of Epanova™, the Company's lead compound for the treatment of patients with very high triglycerides. Epanova is an Omega 3 fatty acid containing a novel formulation of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).
› Verified 2 days ago
| Entity Name | Advanced Cardiovascular Clinic Pc |
|---|---|
| Entity Type | Part B Supplier - Intensive Cardiac Rehabilitation |
| Entity Identifiers | NPI Number: 1912549056 PECOS PAC ID: 7911056882 Enrollment ID: O20191114002122 |
News Archive
The Hospital Universitario Donostia (at the city of Donostia-San Sebasti-n in the Basque province of Gipuzkoa) has incorporated a new glioblastoma multiforme treatment protocol, which could be the starting point for a more effective treatment of this type of cancer. Doctor Nicol-s Sampr-n, specialist in Neurosurgery at the hospital, has presented his PhD at the University of the Basque Country (UPV/EHU) based on the first results of the new treatment method. The work is entitled Glioblastoma multiforme. Analysis of survival and prognostic factors.
Stephen Maturo, MD, of Boston, MA, will receive the first place Charles Ferguson Clinical Science Award for outstanding achievement in the field of pediatric otolaryngology for his research paper titled "Intraoperative Laryngeal Electromyography in Children with Vocal Fold Mobility: Results of a Multicenter Longitudinal Study," during their annual meeting, April 29 - May 1, 2011, in Chicago, IL.
Neuroscientists from the University of Chicago argue that research on how memories form in the brain should consider activity of groups of brain cells working together, not just the connections between them.
Omthera Pharmaceuticals, Inc., a privately-held emerging specialty pharmaceuticals company, today announced that it has reached an agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the design of its planned Phase III registration clinical trial of Epanova™, the Company's lead compound for the treatment of patients with very high triglycerides. Epanova is an Omega 3 fatty acid containing a novel formulation of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mohammad Luay Alkotob, MD, FACC, FSCAI 6122 W Pierson Rd, Unit 1, Flushing, MI 48433-3104 Ph: (810) 600-3399 | Mohammad Luay Alkotob, MD, FACC, FSCAI 6122 W Pierson Rd, Unit 1, Flushing, MI 48433-3104 Ph: (810) 600-3399 |
News Archive
The Hospital Universitario Donostia (at the city of Donostia-San Sebasti-n in the Basque province of Gipuzkoa) has incorporated a new glioblastoma multiforme treatment protocol, which could be the starting point for a more effective treatment of this type of cancer. Doctor Nicol-s Sampr-n, specialist in Neurosurgery at the hospital, has presented his PhD at the University of the Basque Country (UPV/EHU) based on the first results of the new treatment method. The work is entitled Glioblastoma multiforme. Analysis of survival and prognostic factors.
Stephen Maturo, MD, of Boston, MA, will receive the first place Charles Ferguson Clinical Science Award for outstanding achievement in the field of pediatric otolaryngology for his research paper titled "Intraoperative Laryngeal Electromyography in Children with Vocal Fold Mobility: Results of a Multicenter Longitudinal Study," during their annual meeting, April 29 - May 1, 2011, in Chicago, IL.
Neuroscientists from the University of Chicago argue that research on how memories form in the brain should consider activity of groups of brain cells working together, not just the connections between them.
Omthera Pharmaceuticals, Inc., a privately-held emerging specialty pharmaceuticals company, today announced that it has reached an agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the design of its planned Phase III registration clinical trial of Epanova™, the Company's lead compound for the treatment of patients with very high triglycerides. Epanova is an Omega 3 fatty acid containing a novel formulation of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).
› Verified 2 days ago
Kiran Kinra, MD Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 1375 Flushing Rd, Flushing, MI 48433 Phone: 810-659-2233 Fax: 810-659-2246 | |
Imad Issawi, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 6122 W Pierson Rd, Unit 1, Flushing, MI 48433 Phone: 810-600-3399 Fax: 810-600-3398 | |
Madar Abed, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 6122 W Pierson Rd, Unit 1, Flushing, MI 48433 Phone: 810-600-3399 Fax: 810-600-3398 | |
Dr. Maged M Rizk, M.D.,PH.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 754 Bending Ct, Flushing, MI 48433 Phone: 810-867-4883 Fax: 810-867-4883 | |
Dr. Vijay Naraparaju, M.D Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1375 Flushing Rd, Flushing, MI 48433 Phone: 810-659-2233 |